Effect on corpus luteum function of luteal phase administration of a potent gonadotropin-releasing hormone analog (nafarelin).

Schriock ED, Monroe SE, Martin MC, Henzl MR, Jaffe RB

Fertility and sterility1 Jun 1985Cited by 6 (Europe PMC)

PMID3158549DOI10.1016/s0015-0282(16)48610-3PepBankPUB-03158549

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanNon-randomized trialActivity measurement
In women during the luteal phase, all tested single nafarelin doses stimulated LH release.
In plain wordsIn women during the luteal phase, all tested single nafarelin doses stimulated LH release.
Peptide
Nafarelin
Outcome
IncreaseLH stimulation
Study
n = 8
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
single dose of 2, 5 or 100 micrograms · subcutaneousAs given in this study (human).
Source sentences
Summary
All doses stimulated the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
2 context sentences(design, population, supporting numbers)
Summary · context
Eight of the women received a single subcutaneous injection of nafarelin during the luteal phase at a dosage of 2, 5, or 100 micrograms for determination of the dose-response and pharmacokinetic characteristics of the drug.
Summary · context
Fourteen women with ovulatory menstrual cycles were treated with a superactive agonistic analog of gonadotropin-releasing hormone (6-D-[2-naphthyl]-alanyl)-GnRH (nafarelin).
Report a problemFND-0315854901
02HumanNon-randomized trialActivity measurement
In women during the luteal phase, all tested single nafarelin doses stimulated FSH release.
In plain wordsIn women during the luteal phase, all tested single nafarelin doses stimulated FSH release.
Peptide
Nafarelin
Outcome
IncreaseFSH stimulation
Study
n = 8
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
single dose of 2, 5 or 100 micrograms · subcutaneousAs given in this study (human).
Source sentences
Summary
All doses stimulated the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
2 context sentences(design, population, supporting numbers)
Summary · context
Eight of the women received a single subcutaneous injection of nafarelin during the luteal phase at a dosage of 2, 5, or 100 micrograms for determination of the dose-response and pharmacokinetic characteristics of the drug.
Summary · context
Fourteen women with ovulatory menstrual cycles were treated with a superactive agonistic analog of gonadotropin-releasing hormone (6-D-[2-naphthyl]-alanyl)-GnRH (nafarelin).
Report a problemFND-0315854902
03HumanNon-randomized trialActivity measurement
In women receiving daily nafarelin during the luteal phase, gonadotroph desensitization or down-regulation developed within 24 hours.
In plain wordsIn women receiving daily nafarelin during the luteal phase, gonadotroph desensitization developed within 24 hours.
Peptide
Nafarelin
Outcome
Not applicableGonadotroph desensitization
Study
n = 6
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
100 micrograms daily · injectionAs given in this study (human).
Source sentences
Summary
Gonadotroph desensitization or down-regulation developed within 24 hours, but serum concentrations of LH and FSH did not fall below normal values during treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the contraceptive potential of nafarelin as a luteolytic agent, six of the women were treated with 100 micrograms of analog by daily injection for 10 days, beginning either 2 to 3 days or 5 to 7 days after ovulation.
Summary · context
Fourteen women with ovulatory menstrual cycles were treated with a superactive agonistic analog of gonadotropin-releasing hormone (6-D-[2-naphthyl]-alanyl)-GnRH (nafarelin).
Report a problemFND-0315854906
04HumanNon-randomized trialActivity measurement
In women receiving daily luteal-phase nafarelin, serum LH did not fall below normal values.
In plain wordsIn women receiving daily luteal-phase nafarelin, serum LH did not fall below normal values.
Peptide
Nafarelin
Outcome
Not applicableLH relative to normal values
Study
n = 6
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
100 micrograms daily · injection · 10 daysAs given in this study (human).
Source sentences
Summary
Gonadotroph desensitization or down-regulation developed within 24 hours, but serum concentrations of LH and FSH did not fall below normal values during treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the contraceptive potential of nafarelin as a luteolytic agent, six of the women were treated with 100 micrograms of analog by daily injection for 10 days, beginning either 2 to 3 days or 5 to 7 days after ovulation.
Summary · context
Fourteen women with ovulatory menstrual cycles were treated with a superactive agonistic analog of gonadotropin-releasing hormone (6-D-[2-naphthyl]-alanyl)-GnRH (nafarelin).
Report a problemFND-0315854907
05HumanNon-randomized trialActivity measurement
In women receiving daily luteal-phase nafarelin, serum FSH did not fall below normal values.
In plain wordsIn women receiving daily luteal-phase nafarelin, serum FSH did not fall below normal values.
Peptide
Nafarelin
Outcome
Not applicableFSH relative to normal values
Study
n = 6
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
100 micrograms daily · injection · 10 daysAs given in this study (human).
Source sentences
Summary
Gonadotroph desensitization or down-regulation developed within 24 hours, but serum concentrations of LH and FSH did not fall below normal values during treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the contraceptive potential of nafarelin as a luteolytic agent, six of the women were treated with 100 micrograms of analog by daily injection for 10 days, beginning either 2 to 3 days or 5 to 7 days after ovulation.
Summary · context
Fourteen women with ovulatory menstrual cycles were treated with a superactive agonistic analog of gonadotropin-releasing hormone (6-D-[2-naphthyl]-alanyl)-GnRH (nafarelin).
Report a problemFND-0315854908
06HumanNon-randomized trialActivity measurement
In women receiving daily luteal-phase nafarelin, mean estradiol did not change significantly.
In plain wordsIn women receiving daily luteal-phase nafarelin, mean estradiol did not change significantly.
Peptide
Nafarelin
Outcome
No significant changeMean estradiol
Study
n = 6
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
100 micrograms daily · injection · 10 daysAs given in this study (human).
Source sentences
Summary
There were no significant changes in mean estradiol or progesterone concentrations.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the contraceptive potential of nafarelin as a luteolytic agent, six of the women were treated with 100 micrograms of analog by daily injection for 10 days, beginning either 2 to 3 days or 5 to 7 days after ovulation.
Summary · context
Fourteen women with ovulatory menstrual cycles were treated with a superactive agonistic analog of gonadotropin-releasing hormone (6-D-[2-naphthyl]-alanyl)-GnRH (nafarelin).
Report a problemFND-0315854909
07HumanNon-randomized trialActivity measurement
In women receiving daily luteal-phase nafarelin, mean progesterone did not change significantly.
In plain wordsIn women receiving daily luteal-phase nafarelin, mean progesterone did not change significantly.
Peptide
Nafarelin
Outcome
No significant changeMean progesterone
Study
n = 6
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
100 micrograms daily · injection · 10 daysAs given in this study (human).
Source sentences
Summary
There were no significant changes in mean estradiol or progesterone concentrations.
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the contraceptive potential of nafarelin as a luteolytic agent, six of the women were treated with 100 micrograms of analog by daily injection for 10 days, beginning either 2 to 3 days or 5 to 7 days after ovulation.
Summary · context
Fourteen women with ovulatory menstrual cycles were treated with a superactive agonistic analog of gonadotropin-releasing hormone (6-D-[2-naphthyl]-alanyl)-GnRH (nafarelin).
Report a problemFND-0315854910
08HumanNon-randomized trialActivity measurement
In women, mean luteal phase length was unchanged with daily nafarelin: 13.7 +/- 2.1 control versus 13.6 +/- 1.4 days.
In plain wordsIn women, daily luteal-phase nafarelin did not change mean luteal phase length compared with control cycles.
Peptide
Nafarelin
Outcome
No significant changeMean luteal phase length
Study
n = 6
Comparator
control cycles
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
100 micrograms daily · injection · 10 daysAs given in this study (human).
Measurements
Luteal phase length, mean
13.7 days
control
Luteal phase length, SD
2.1 days
control
Luteal phase length, mean
13.6 days
daily nafarelin 100 micrograms
Luteal phase length, SD
1.4 days
daily nafarelin 100 micrograms
Source sentences
Summary
There also was no change in mean length of the luteal phase (13.7 +/- 2.1 days [control] versus 13.6 +/- 1.4 days).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the contraceptive potential of nafarelin as a luteolytic agent, six of the women were treated with 100 micrograms of analog by daily injection for 10 days, beginning either 2 to 3 days or 5 to 7 days after ovulation.
Summary · context
Fourteen women with ovulatory menstrual cycles were treated with a superactive agonistic analog of gonadotropin-releasing hormone (6-D-[2-naphthyl]-alanyl)-GnRH (nafarelin).
Report a problemFND-0315854911
09HumanNon-randomized trialActivity measurement
In women during the luteal phase, 5 micrograms of nafarelin produced a maximal LH increase of 297 +/- 75 mIU/ml.
In plain wordsIn women during the luteal phase, nafarelin at 5 micrograms produced maximal LH release.
Peptide
Nafarelin
Outcome
IncreaseMaximal LH release
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
5 micrograms · subcutaneousAs given in this study (human).
Measurements
Delta LH, mean
297 mIU/ml
5 micrograms dose
Delta LH, SD
75 mIU/ml
5 micrograms dose
Source sentences
Summary
Maximal release was obtained with the 5-micrograms dose (mean +/- standard deviation: delta LH = 297 +/- 75 mIU/ml; delta FSH = 29 +/- 7 mIU/ml), and there was no greater release of gonadotropin with the 100-micrograms dose.
1 context sentence(design, population, supporting numbers)
Summary · context
Fourteen women with ovulatory menstrual cycles were treated with a superactive agonistic analog of gonadotropin-releasing hormone (6-D-[2-naphthyl]-alanyl)-GnRH (nafarelin).
Report a problemFND-0315854903
10HumanNon-randomized trialActivity measurement
In women during the luteal phase, 5 micrograms of nafarelin produced a maximal FSH increase of 29 +/- 7 mIU/ml.
In plain wordsIn women during the luteal phase, nafarelin at 5 micrograms produced maximal FSH release.
Peptide
Nafarelin
Outcome
IncreaseMaximal FSH release
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
5 micrograms · subcutaneousAs given in this study (human).
Measurements
Delta FSH, mean
29 mIU/ml
5 micrograms dose
Delta FSH, SD
7 mIU/ml
5 micrograms dose
Source sentences
Summary
Maximal release was obtained with the 5-micrograms dose (mean +/- standard deviation: delta LH = 297 +/- 75 mIU/ml; delta FSH = 29 +/- 7 mIU/ml), and there was no greater release of gonadotropin with the 100-micrograms dose.
1 context sentence(design, population, supporting numbers)
Summary · context
Fourteen women with ovulatory menstrual cycles were treated with a superactive agonistic analog of gonadotropin-releasing hormone (6-D-[2-naphthyl]-alanyl)-GnRH (nafarelin).
Report a problemFND-0315854904
11HumanNon-randomized trialActivity measurement
In women during the luteal phase, nafarelin at 100 micrograms produced no greater gonadotropin release than 5 micrograms.
In plain wordsIn women during the luteal phase, nafarelin at 100 micrograms produced no greater gonadotropin release than 5 micrograms.
Peptide
Nafarelin
Outcome
No significant changeGonadotropin release dose comparison
Study
n: not reported in source
Comparator
5 micrograms nafarelin
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
100 micrograms · subcutaneousAs given in this study (human).
Source sentences
Summary
Maximal release was obtained with the 5-micrograms dose (mean +/- standard deviation: delta LH = 297 +/- 75 mIU/ml; delta FSH = 29 +/- 7 mIU/ml), and there was no greater release of gonadotropin with the 100-micrograms dose.
1 context sentence(design, population, supporting numbers)
Summary · context
Fourteen women with ovulatory menstrual cycles were treated with a superactive agonistic analog of gonadotropin-releasing hormone (6-D-[2-naphthyl]-alanyl)-GnRH (nafarelin).
Report a problemFND-0315854905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.